Matrixyl Limited Evidence

What It Is

Matrixyl is a trade name owned by Sederma (a subsidiary of Croda International) for a family of palmitoylated short peptides used as active ingredients in topical anti-aging cosmetics. The "original" Matrixyl is Palmitoyl Pentapeptide-4, a five-amino-acid sequence — lysine-threonine-threonine-lysine-serine, abbreviated KTTKS — conjugated at the N-terminus to a 16-carbon palmitic acid chain. The resulting molecule, Pal-KTTKS, has a molecular weight of roughly 802 Da and a CAS registry number of 214047-00-4.

The KTTKS sequence is not an invented synthetic — it corresponds exactly to residues 212 through 216 of the C-terminal propeptide of human type I procollagen, the globular "tail" that is cleaved off procollagen molecules when they are processed into mature collagen fibrils in the extracellular matrix. In the early 1990s, Katayama and colleagues at the University of Tennessee Health Science Center (Memphis) demonstrated that synthetic KTTKS dramatically increased type I and III collagen and fibronectin production by human fibroblasts at concentrations as low as 10^-12 M (Katayama et al., Biochemistry 1991; Katayama et al., J Biol Chem 1993, PMID 8486721). This placed KTTKS in the category of matrikines — extracellular-matrix-derived fragments that feed back on cells to regulate matrix homeostasis.

Native KTTKS is a problem for topical delivery: it is small, highly hydrophilic, and cationic (two lysines), which makes penetration of the lipophilic stratum corneum inefficient. Sederma's technical innovation, commercialized in the late 1990s, was to N-terminally conjugate KTTKS with palmitic acid. The resulting palmitoyl pentapeptide is amphiphilic — a lipophilic tail attached to a hydrophilic "head" — and is dramatically more stable against proteolytic degradation in the dermis than the parent peptide while retaining the collagen-stimulating signaling activity (Choi et al., Biomol Ther 2014, PMID 25143811; Mortazavi et al., J Cosmet Sci 2019, PMID 31829923).

Since the launch of the original Matrixyl, Sederma has extended the trade name to cover two further, mechanistically distinct products:

• Matrixyl 3000 — A 1:1 combination of Palmitoyl Tripeptide-1 (Pal-GHK — the palmitoylated form of glycyl-histidyl-lysine, the endogenous matrikine usually paired with copper as GHK-Cu) and Palmitoyl Tetrapeptide-7 (Pal-GQPR — glycyl-glutaminyl-prolyl-arginine, a fragment of immunoglobulin G that modulates IL-6 and inflammatory extracellular matrix breakdown). Marketed as a broader-spectrum matrikine complex than Pal-KTTKS alone.
• Matrixyl synthe'6 — Palmitoyl Tripeptide-38, a palmitoylated lysyl-methioninyl-oxo-methioninyl-lysine ("KMO₂K") motif that Sederma derives from sequences found in tenascin-X, laminin, and collagen VI. Marketed as upregulating six structural extracellular matrix components: collagen I, III, IV, fibronectin, hyaluronic acid, and laminin-5.

All Matrixyl variants share three defining features: they are short (3–5 amino acids), they are palmitoylated at the N-terminus for skin permeation, and they are marketed as matrikine-class signaling molecules rather than as "replacement" ingredients (unlike, for example, hyaluronic acid or collagen hydrolysates, which act as bulk substrates). Matrixyl is sold to cosmetic formulators as an aqueous or glyceric concentrate typically containing 100–500 ppm of the active palmitoyl peptide; end-product formulations usually incorporate 3–8% of this concentrate, delivering 3–40 ppm active peptide at the point of use.

The Matrixyl family sits alongside — and is often co-formulated with — other cosmetic peptides on this site: Argireline (acetyl hexapeptide-8, a SNAP-25-mimetic neuromodulator), Pal-GHK (palmitoylated GHK, the tripeptide-1 component of Matrixyl 3000), Syn-Coll (palmitoyl tripeptide-5), AHK-Cu (alanyl-histidyl-lysine-copper), Syn-Ake (a dipeptide snake-venom mimic), and GHK-Cu itself. The category is properly understood as "cosmetic signaling peptides" — topical actives with real but modest evidence bases designed to modulate skin biology through short-sequence signaling motifs.

Mechanism of Action

The mechanistic basis for Matrixyl is one of the more carefully worked-out stories in cosmetic peptide science. The data are drawn from in vitro fibroblast culture work in the 1990s and 2000s and from a smaller number of ex vivo human skin studies; they support — rather than fully prove — the clinical claims.

• KTTKS is a procollagen I C-propeptide matrikine — The parent pentapeptide is a strict sub-fragment of the type I procollagen carboxy-terminal propeptide (residues 212–216, a region also called the "C-pentapeptide"). The C-propeptide is enzymatically cleaved off procollagen during extracellular maturation; free C-propeptide and its sub-fragments have been shown to feed back on fibroblasts to regulate new collagen synthesis, with different regions acting as positive and negative signals. Katayama's original 1991 and 1993 work identified the 45-amino-acid 197–241 fragment as the most potent positive feedback region, and then dissected KTTKS as the minimum five-residue active sub-fragment (Katayama et al., Biochemistry 1991; Katayama et al., J Biol Chem 1993, PMID 8486721).
• Upregulation of collagen I and III synthesis in fibroblasts — KTTKS and Pal-KTTKS both increase the secretion of type I and type III collagen by cultured human and rodent fibroblasts in a dose- and time-dependent manner, with threshold effects at nanomolar to sub-nanomolar concentrations. The response appears to be transcriptional — α1(I) procollagen mRNA is upregulated and stabilized — rather than a non-specific growth-factor effect. The stimulation is selective: total protein synthesis is not changed, and the ratio of secreted to cell-associated protein is preserved.
• Fibronectin and glycosaminoglycan upregulation — In the same concentration range, Pal-KTTKS stimulates fibronectin production by 50–200% and increases glycosaminoglycan (GAG) synthesis, contributing to extracellular matrix volume and mechanical integrity. The CIR safety review cites supplier data on roughly 30% de novo hyaluronic acid synthesis at cosmetically relevant concentrations (CIR, 2024).
• TGF-β upregulation in tendon and skin fibroblasts — Work from Tsai and colleagues in tendon-derived fibroblasts showed that KTTKS upregulates α1(I) procollagen mRNA expression, slows α1(I) procollagen mRNA degradation, and dose-dependently increases TGF-β secretion into conditioned media — consistent with TGF-β being one of the autocrine/paracrine mediators of the KTTKS effect on the extracellular matrix (Tsai et al., J Orthop Res 2007).
• Type IV collagen and basement membrane support — Supplier data summarized in the CIR safety review and the published cosmeceutical literature indicate that Pal-KTTKS also modulates type IV collagen — the major structural component of the dermal-epidermal basement membrane — consistent with its marketing as a broad "extracellular matrix" stimulator rather than a pure fibrillar-collagen agent.
• Self-assembly into nanotape structures above a critical aggregation concentration — Hamley and colleagues at the University of Reading have shown that Pal-KTTKS spontaneously self-assembles into β-sheet nanotapes in aqueous solution above a critical aggregation concentration. Collagen stimulation in dermal and corneal fibroblasts appears to peak near this self-assembly threshold, suggesting that the supramolecular nanotape state (rather than free monomer) may be the signaling-competent form (Jones et al., Mol Pharm 2013, PMID 23320752; Castelletto & Hamley et al., Langmuir 2013).
• Palmitoyl chain as permeation vehicle and stability enhancer — The C16 palmitoyl tail dramatically increases lipophilicity, enabling partitioning into the stratum corneum lipid lamellae. Pal-KTTKS has demonstrably greater skin permeability and dermal stability than unmodified KTTKS in hairless mouse and reconstructed human skin models (Choi et al., Biomol Ther 2014, PMID 25143811; Mortazavi et al., J Cosmet Sci 2019, PMID 31829923). Stability gains are large: unmodified KTTKS is rapidly degraded by dermal proteases, whereas Pal-KTTKS retains its primary sequence for hours under the same conditions.
• Wound-healing and α-SMA modulation — Park et al. (Tissue Eng Regen Med 2017, PMID 30603464) found that Pal-KTTKS modulates connective tissue growth factor (CTGF) expression and α-smooth muscle actin (α-SMA) in fibroblasts, suggesting effects on fibroblast-to-myofibroblast trans-differentiation relevant to wound contraction and potentially to scar morphology. The clinical relevance of this finding for cosmetic anti-aging use is unclear.
• Matrixyl 3000 (Pal-GHK + Pal-GQPR) mechanism — The Pal-GHK component engages the same matrikine pathway as endogenous GHK-Cu: upregulation of collagen, decorin, and glycosaminoglycan synthesis; modulation of metalloproteinase-2; promotion of fibroblast migration. The Pal-GQPR component is a palmitoylated IgG hinge-region tetrapeptide that has been reported to suppress IL-6-driven inflammatory signaling and to down-regulate matrix-degrading proteases — the combination is marketed as a balanced "builder + protector" dual matrikine complex.
• Matrixyl synthe'6 (Pal-Tripeptide-38) mechanism — Supplier data indicate that Pal-KMO₂K upregulates six extracellular matrix components (collagen I, III, IV, fibronectin, hyaluronic acid, laminin-5) and aquaporin-3 in keratinocytes and fibroblasts. Independent mechanistic validation of Pal-Tripeptide-38 is substantially thinner than for Pal-KTTKS and largely limited to manufacturer-disclosed experiments.
• What is not well established — No single canonical membrane receptor for KTTKS has been cloned. The upstream receptor is presumed to be a surface binding partner present on fibroblasts and keratinocytes, but the identity of the receptor and the exact signal transduction cascade (PI3K/Akt? MAP kinase? Smad-independent TGF-β autocrine loop?) remain under-characterized compared with more thoroughly dissected peptides on this site. Claims that Matrixyl "activates" any specific named pathway should be read as extrapolation from ECM/TGF-β/matrikine biology rather than as proven receptor-level pharmacology.

What the Research Shows

The Matrixyl clinical literature is small, industry-adjacent, and technically modest — but it is not empty. There is one reasonably well-powered split-face randomized controlled trial, a handful of smaller manufacturer-sponsored studies, and a number of narrative reviews. The research-quality profile is typical of a cosmetic ingredient: bioactive on a coherent in vitro mechanism, with clinical endpoints that are mostly subjective and manufacturer-involved.

• Robinson 2005 — 12-week split-face RCT in photoaged Caucasian women — Robinson and colleagues at Procter & Gamble's Miami Valley Laboratories conducted a 12-week, double-blind, placebo-controlled, split-face, left-right randomized clinical study in 93 Caucasian women aged 35–55 (Int J Cosmet Sci 2005, PMID 18492182). Each subject applied moisturizer containing 3 ppm Pal-KTTKS to one half of the face and matching vehicle moisturizer to the other. Pal-KTTKS produced statistically significant improvement versus vehicle on quantitative wrinkle / fine-line measures by both technical image analysis and expert grader evaluation. Subject self-assessment showed the same pattern. Skin tolerability was equivalent to vehicle. This remains the single most-cited clinical support for Matrixyl's cosmetic claims.
• Osborne 2005 — 8-week split-face moisturizer study (n=60) — Osborne and colleagues (also at P&G) evaluated a daily-use facial moisturizer containing Pal-KTTKS combined with niacinamide versus moisturizer alone in 60 women aged 35–65, applied twice daily for 8 weeks in a split-face, randomized, round-robin design (Osborne, Robinson, Mullins, Raleigh; J Am Acad Dermatol 2005 abstract/poster, published in JAAD as part of the AAD meeting proceedings). The moisturizer containing Pal-KTTKS plus niacinamide produced greater improvement in skin texture, fine lines, and wrinkle appearance at the cheek and periorbital area than moisturizer alone. Study design was technically sound for a cosmetic endpoint but used subjective expert-grading and self-report as primary outcomes.
• Lupo 2005 — Dermatologic Surgery narrative review — Mary P. Lupo of Tulane University reviewed the emerging cosmeceutical peptide category (Dermatol Surg 2005, PMID 16029675). Pal-KTTKS was positioned as a signal-peptide class representative; the review concluded that there is "science that shows these peptide cosmeceuticals have the potential to improve the appearance of aging skin" while emphasizing that stability, penetration, and bioactivity at the target must all be demonstrated for clinical benefit.
• Lupo & Cole 2007 — Dermatologic Therapy update — Lupo and Cole updated the category in 2007 (Dermatol Ther 2007, PMID 18045359), grouping cosmeceutical peptides into signal peptides, neurotransmitter-affecting peptides, and carrier peptides. The review reaffirms the signal-peptide classification of Pal-KTTKS and notes that while benefits are "not as rigorously tested as most FDA-regulated drugs, the evidence to support their use is growing."
• Trookman 2009 — Topical facial serum (n=79, 8 weeks) — Trookman, Rizer, Ford, Ho, and Gotz evaluated a topical facial treatment containing Pal-KTTKS in an 8-week clinical study of subjects with fine lines and wrinkles (J Clin Aesthet Dermatol 2009, PMID 20729942). Expert-grader assessment found statistically significant improvements in fine lines and wrinkles by week 2 and continued improvement through week 8. The study was sponsored by SkinMedica (the product manufacturer) and used expert-grader visual assessment as the primary endpoint.
• Fu 2010 — Niacinamide/peptide/retinyl propionate vs 0.02% tretinoin (n=196) — Fu, Hillebrand, Raleigh and colleagues ran a 24-week randomized, controlled comparative trial pitting a cosmetic niacinamide/peptide (Pal-KTTKS)/retinyl-propionate regimen against prescription 0.02% tretinoin in 196 women with moderate facial photoageing (Br J Dermatol 2010, PMID 20374604). Both regimens produced significant wrinkle reduction from baseline; the cosmetic regimen was comparable to tretinoin by week 8 and slightly less effective by week 24. Tolerability favored the cosmetic regimen. This trial is the best direct-head-to-head data available for a Pal-KTTKS-containing product.
• Gorouhi & Maibach 2009 — Int J Cosmet Sci peptide review — Gorouhi and Maibach (UCSF Dermatology) systematically categorized topical peptides for aged skin into signal, neurotransmitter, carrier, and enzyme-inhibitor groups (Int J Cosmet Sci 2009, PMID 19570099). Pal-KTTKS is classified as a signal peptide; the review is cautiously positive, repeatedly notes the industry sponsorship of the primary efficacy literature, and emphasizes the need for independent confirmation.
• Jones 2013 — Collagen stimulation and nanotape self-assembly — Jones, Castelletto, Connon, and Hamley (University of Reading) directly measured collagen production by human dermal and corneal fibroblasts exposed to Pal-KTTKS across a concentration range (Mol Pharm 2013, PMID 23320752). Pal-KTTKS stimulated collagen in a dose-dependent fashion with maximum effect near the critical aggregation concentration at which it self-assembles into β-sheet nanotapes, supporting a supramolecular signaling mechanism.
• Choi 2014 — Dermal stability and skin permeation — Choi and colleagues measured dermal stability and in vitro skin permeation of KTTKS and Pal-KTTKS through hairless mouse skin (Biomol Ther 2014, PMID 25143811). Pal-KTTKS was substantially more stable against degradation in the dermis and showed higher steady-state permeation flux than unmodified KTTKS — direct experimental support for the palmitoylation-as-delivery-vehicle design rationale.
• Park 2017 — Wound contractility and myofibroblast signaling — Park, An, and Cho Lee studied Pal-KTTKS effects on fibroblast contractility, CTGF expression, and α-SMA expression in vitro (Tissue Eng Regen Med 2017, PMID 30603464), reporting modulation of myofibroblast trans-differentiation at pharmacologically relevant concentrations.
• Tałałaj 2019 — KTTKS analogue structure-activity series — Tałałaj and colleagues synthesized a series of KTTKS analogues with different N-terminal lipid modifications (acetyl, lipoyl, palmitoyl) and evaluated cytotoxicity and proteolytic activity against urokinase, thrombin, trypsin, plasmin, t-PA, and kallikrein (Molecules 2019, PMID 31618846). The palmitoyl variant maintained favorable cytotoxicity and added plasmin-inhibitory activity — a new potential mechanistic dimension beyond pure collagen stimulation.
• Vitali 2024 — Liposome encapsulation of Pal-KTTKS — Vitali and colleagues characterized liposome-encapsulated Pal-KTTKS formulations for enhanced stability and delivery, demonstrating in vitro collagen-I stimulation in 3T3-NIH fibroblasts and maintained cell viability at cosmetically relevant concentrations (Pharmaceutics 2024, PMID 38399273).

Human Data

Matrixyl's human data are entirely topical-cosmetic. There are no systemic or parenteral human trials — the route is topical only, the indications are cosmetic (fine lines, wrinkles, texture, firmness), and the primary endpoints are dermatologist or subject visual assessments. The most important trials:

• Robinson 2005 (PMID 18492182) — 93 Caucasian women, 35–55 years old, 12 weeks, double-blind split-face randomized vehicle-controlled. 3 ppm Pal-KTTKS in moisturizer vs identical moisturizer vehicle. Significant Pal-KTTKS superiority on quantitative image analysis wrinkle/fine-line reduction and on expert-grader assessment. No safety signal.
• Osborne 2005 (JAAD abstract / AAD proceedings) — 60 women, 35–65 years, 8 weeks, split-face, randomized round-robin. Moisturizer + niacinamide + Pal-KTTKS vs moisturizer alone. Significant improvement in skin texture, fine lines, and cheek/eye wrinkle appearance. Combination design cannot isolate Pal-KTTKS contribution.
• Trookman 2009 (PMID 20729942) — 8-week open-label evaluation of a Pal-KTTKS-containing facial serum (SkinMedica TNS Recovery Complex / related formulation). Significant improvements in fine lines and wrinkles by week 2, sustained to week 8, on expert-grader and self-report endpoints. Manufacturer-sponsored; no placebo arm.
• Fu 2010 (PMID 20374604) — 196 women, 24-week, randomized controlled head-to-head trial of a cosmetic niacinamide/Pal-KTTKS/retinyl-propionate regimen vs prescription 0.02% tretinoin. Both regimens produced significant wrinkle reduction from baseline on expert-grader and image analysis endpoints; the cosmetic regimen was comparable to tretinoin at 8 weeks and slightly inferior at 24 weeks. Tolerability clearly favored the cosmetic regimen.
• Ex vivo / in vitro-to-clinical bridging — Several published series have used short-duration (4–8 week) bioinstrumentation studies (corneometer hydration, cutometer elasticity, silicone replica roughness) rather than expert-grader wrinkle scales. These report favorable directional effects for Pal-KTTKS-containing formulations but are not themselves randomized clinical trials.
• Matrixyl 3000 (Pal-GHK + Pal-GQPR) human data — Manufacturer-disclosed 2-month open-label studies reported roughly 30–45% reduction in wrinkle density and depth. These results circulate in the cosmetic literature but have not been replicated in an independent peer-reviewed vehicle-controlled RCT at the level of the Robinson 2005 Pal-KTTKS trial.
• Matrixyl synthe'6 (Pal-Tripeptide-38) human data — Supplier-disclosed 2-month studies report reductions in forehead and crow's-feet wrinkle depth. Independent peer-reviewed vehicle-controlled RCT data at the Robinson 2005 level of rigor are not currently available.
• Systemic exposure — No measurable systemic absorption has been demonstrated from cosmetic concentrations of Pal-KTTKS. The molecule is too large and too lipophilic-at-the-tail, too hydrophilic-at-the-head to cross the intact stratum corneum in pharmacologically meaningful amounts under normal cosmetic use conditions. Bloodwork changes are not expected and have not been reported.

The 2024 CIR (Cosmetic Ingredient Review) expert panel re-assessment of myristoyl pentapeptide-4, palmitoyl pentapeptide-4, and pentapeptide-4 compiled supplier-provided and published safety, exposure, and efficacy data and concluded these ingredients are safe as used in cosmetic formulations at current concentrations and exposure patterns. The CIR review is the most comprehensive single consolidation of the safety-and-exposure side of the Matrixyl human data.

Dosing from the Literature

Matrixyl dosing applies to topical cosmetic formulations only. There is no parenteral or oral dose regimen; Matrixyl is never injected or ingested. The convention is to express dose either as percent of the commercial Sederma concentrate (Matrixyl 3000, synthe'6, etc.) or as ppm of the active palmitoyl peptide in the final formulation.

Application pattern in the clinical literature is consistent: twice-daily application to the target skin area (face, neck, décolleté, hands) after cleansing, before sunscreen. Effect onset in clinical trials is measurable at 2–4 weeks, with full plateau typically at 8–12 weeks. Effect magnitude is modest but real in the clinical range (roughly 15–30% reduction in wrinkle score by the vehicle-controlled Robinson 2005 study, equivalent to the lower end of the retinoid range).

→ Use the Kalios Dosing Calculator for topical formulation ppm conversions

Reconstitution & Storage

Matrixyl does not require reconstitution in the classical peptide sense — commercial Matrixyl variants are sold to formulators as ready-to-blend aqueous or glyceric solutions. Research-grade Pal-KTTKS powder, however, does require careful formulation for stability and delivery.

• Incompatibilities — Avoid high-pH (>7.5) formulations; avoid strong oxidizers (benzoyl peroxide, hypochlorites) and strongly ionic actives that may destabilize the supramolecular assembly. Routine cosmetic co-formulation with retinoids, niacinamide, hyaluronic acid, vitamin C derivatives, and antioxidants is standard and has been done safely in published clinical trials (Fu 2010).
• Preservation — Matrixyl formulations are aqueous and require a broad-spectrum preservative system (phenoxyethanol + caprylyl glycol, benzyl alcohol + dehydroacetic acid, or modern preservative blends). Peptides themselves are susceptible to proteolytic contaminants — maintain low-bioburden manufacturing conditions.
• Packaging — Use opaque, air-limiting packaging (airless pump, tubes, amber glass) to protect against oxidation and photodegradation. Palmitoyl peptides are reasonably photostable but still benefit from standard cosmetic light-protection practice.
• Research-grade handling — For researchers working with neat Pal-KTTKS powder, dissolve in a 50:50 water:glycerin or water:propylene glycol vehicle at 0.1–0.5% (1,000–5,000 ppm) stock, then dilute into final formulation to the target 3–10 ppm. Vortex thoroughly; allow 24-hour equilibration for self-assembly to reach nanotape steady state.
• Biological inactivation — Discard any formulation that shows cloudiness, discoloration, or separation; peptide degradation products may no longer carry the signaling activity.

→ Use the Kalios Dosing Calculator for topical ppm and percent-concentrate conversions

Side Effects & Risks

Matrixyl's safety profile is among the mildest in this database — consistent with its topical route, short peptide structure, large molecular weight relative to classical small-molecule actives, and extensive global consumer exposure over two decades. The Cosmetic Ingredient Review (CIR) Expert Panel has assessed myristoyl pentapeptide-4, palmitoyl pentapeptide-4, and pentapeptide-4 and concluded they are safe as used in current cosmetic formulations (CIR Safety Assessment, 2024 and preceding documents).

• Skin tolerance — In Robinson 2005 (n=93 split-face, 12 weeks), Pal-KTTKS was "well tolerated by the skin" and produced no more skin irritation or stinging than the vehicle moisturizer. This is a consistent finding across the cosmetic literature at 3–10 ppm use concentration.
• Contact irritation / sensitization — Rare case reports of cosmetic contact dermatitis to Matrixyl-containing formulations exist, but in most cases the cause has been traced to other formulation components (preservatives, fragrance, essential oils) rather than the peptide itself. Patch testing on clean positive reactions is unusual.
• Fragrance- / preservative-driven reactions — Most reported adverse reactions to "Matrixyl creams" in the general cosmetic complaint literature are driven by the full formulation rather than the peptide. Patch testing, where performed, typically implicates other ingredients.
• Periorbital use — Matrixyl is used in eye creams without unusual risk to the ocular surface; still, avoid direct contact with the eye and rinse if product enters.
• Pregnancy and lactation — Systemic absorption of Pal-KTTKS at cosmetic concentrations is not pharmacologically meaningful, and no specific pregnancy safety signal has been identified. Absence of evidence is not evidence of absence, however; conservative practice is to minimize use of any cosmetic active during pregnancy unless specifically needed.
• Pediatric use — Matrixyl is marketed as an anti-aging cosmetic; use in minors is uncommon and not clinically indicated. No specific pediatric safety data.
• Drug interactions — Topical cosmetic peptides at 3–10 ppm with no systemic absorption do not produce clinically meaningful drug interactions. Concurrent topical retinoid or exfoliating-acid use may modestly increase local irritation of the combined regimen; this is a formulation-level effect rather than a Matrixyl-specific interaction.
• Photosensitivity — Matrixyl itself is not a photosensitizer; daily sunscreen use is nonetheless strongly recommended as part of any anti-aging topical regimen because UV exposure directly drives photoaging that Matrixyl is attempting to counter.
• Long-term safety — Two decades of global cosmetic consumer exposure to Pal-KTTKS, Pal-GHK, Pal-GQPR, and Pal-Tripeptide-38 have not surfaced unanticipated long-term safety signals. Cumulative usage data are informal but substantial.
• Not a drug — Matrixyl is a cosmetic ingredient, not an FDA-approved drug. It does not treat or cure any disease, and any claim of "treatment" is regulatory miscategorization. Structure-function claims at the cosmetic level (improves appearance of fine lines, wrinkles, texture) are permitted; disease claims are not.
• Growth-factor concerns — Unlike true growth-factor cosmetics (EGF, bFGF, KGF preparations), Pal-KTTKS is a short peptide matrikine with no receptor-tyrosine-kinase agonist activity of the kind that underlies theoretical proliferation concerns with large-molecule growth-factor products. The theoretical pro-proliferative concern that has been raised for growth-factor cosmetics does not straightforwardly extend to KTTKS-class matrikines.

Bloodwork & Monitoring

Matrixyl is a topical cosmetic peptide with no meaningful systemic absorption at normal cosmetic concentrations. Routine bloodwork or systemic monitoring is not indicated for topical cosmetic use.

• No standard bloodwork panel — Unlike injectable or oral peptides on this site, there is no CMP, CBC, or hormone panel considered standard for Matrixyl users. The ingredient is not systemically bioavailable in pharmacologically meaningful amounts from cosmetic application.
• Skin monitoring — self-assessment — Photographic self-monitoring at weeks 0, 4, 8, and 12 under consistent lighting is the most useful "monitoring" pattern. Objective change is modest and typically becomes visible at weeks 4–8 in responders.
• Skin monitoring — clinical — For clinical research or dermatology practice settings, standard cosmetic endpoints include silicone replica + profilometry, expert-grader wrinkle scales (e.g., Griffiths photoaging scale), corneometer hydration, cutometer elasticity, and high-resolution photographic image analysis. None of these is required for personal cosmetic use.
• Irritation / sensitization patch testing — Prior to full-face use, a patch test on the inner forearm or behind the ear for 48 hours is sensible for any new topical active, including Matrixyl. Discontinue and consult a dermatologist if reaction occurs.
• Expectation setting — Effect size is modest by design. Users expecting tretinoin-level results from a Matrixyl-only regimen are likely to be disappointed. Users combining Matrixyl with appropriate sunscreen, retinoids, and antioxidants are more likely to see clinically meaningful improvement.

Commonly Stacked With

Matrixyl is frequently combined in cosmetic formulations with other peptide and non-peptide actives. The pairings below are based on published cosmetic literature and/or standard Sederma formulation guidance.

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

Matrikine and related cosmetic peptides to cross-reference:

Next Steps

Key References

1. Katayama K, Armendariz-Borunda J, Raghow R, Kang AH, Seyer JM. A pentapeptide from type I procollagen promotes extracellular matrix production. J Biol Chem. 1993;268(14):9941-9944. PMID: 8486721. (The defining paper identifying KTTKS as the minimum collagen-stimulating sub-fragment of the type I procollagen C-propeptide.)
2. Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005;27(3):155-160. PMID: 18492182. (The 93-subject 12-week split-face vehicle-controlled RCT of 3 ppm Pal-KTTKS — the single best clinical-trial support for Matrixyl.)
3. Lupo MP. Cosmeceutical peptides. Dermatol Surg. 2005;31(7 Pt 2):832-836. PMID: 16029675. (Category-defining review placing Pal-KTTKS in the signal-peptide class of cosmeceuticals.)
4. Lupo MP, Cole AL. Cosmeceutical peptides. Dermatol Ther. 2007;20(5):343-349. PMID: 18045359. (Updated Dermatologic Therapy review of signal, neurotransmitter-affecting, and carrier peptides.)
5. Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31(5):327-345. PMID: 19570099. (UCSF Dermatology systematic review of topical peptides for aged skin, including Pal-KTTKS signal-peptide class.)
6. Trookman NS, Rizer RL, Ford R, Ho E, Gotz V. Immediate and Long-term Clinical Benefits of a Topical Treatment for Facial Lines and Wrinkles. J Clin Aesthet Dermatol. 2009;2(3):38-43. PMID: 20729942. (8-week topical treatment clinical study including palmitoyl pentapeptide active; SkinMedica-sponsored.)
7. Fu JJ, Hillebrand GG, Raleigh P, Li J, Marmor MJ, Bertucci V, Grimes PE, Mandy SH, Perez MI, Weinkle SH, Kaczvinsky JR. A randomized, controlled comparative study of the wrinkle reduction benefits of a cosmetic niacinamide/peptide/retinyl propionate product regimen vs. a prescription 0.02% tretinoin product regimen. Br J Dermatol. 2010;162(3):647-654. PMID: 20374604. (24-week head-to-head RCT of cosmetic Pal-KTTKS-containing regimen vs prescription tretinoin.)
8. Jones RR, Castelletto V, Connon CJ, Hamley IW. Collagen stimulating effect of peptide amphiphile C16-KTTKS on human fibroblasts. Mol Pharm. 2013;10(3):1063-1069. PMID: 23320752. (Direct fibroblast collagen-production dose-response for Pal-KTTKS linked to critical-aggregation-concentration self-assembly.)
9. Choi YL, Park EJ, Kim E, Na DH, Shin YH. Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS). Biomol Ther (Seoul). 2014;22(4):321-327. PMID: 25143811. (Demonstrates palmitoylation as stability and permeation enhancer relative to unmodified KTTKS.)
10. Park H, An E, Cho Lee AR. Effect of Palmitoyl-Pentapeptide (Pal-KTTKS) on Wound Contractile Process in Relation with Connective Tissue Growth Factor and α-Smooth Muscle Actin Expression. Tissue Eng Regen Med. 2017;14(1):73-80. PMID: 30603464. (CTGF / α-SMA modulation and fibroblast-to-myofibroblast effects of Pal-KTTKS.)
11. Tałałaj U, Uscinowicz P, Bruzgo I, Surazynski A, Zareba I, Markowska A. The Effects of a Novel Series of KTTKS Analogues on Cytotoxicity and Proteolytic Activity. Molecules. 2019;24(20):3698. PMID: 31618846. (Structure-activity series of KTTKS analogues with acetyl / lipoyl / palmitoyl N-terminal modifications.)
12. Mortazavi SM, Kobarfard F, Maibach HI, Moghimi HR. Effect of Palmitic Acid Conjugation on Physicochemical Properties of Peptide KTTKS: A Preformulation Study. J Cosmet Sci. 2019;70(6):299-312. PMID: 31829923. (Physicochemical characterization of palmitoyl conjugation effects on KTTKS — lipophilicity, stability, aggregation behavior.)
13. Vitali A, Paolicelli P, Bigi B, Trilli J, Di Muzio L, Carriero VC, Casadei MA, Petralito S. Liposome Encapsulation of the Palmitoyl-KTTKS Peptide: Structural and Functional Characterization. Pharmaceutics. 2024;16(2):219. PMID: 38399273. (Liposomal delivery system for Pal-KTTKS with maintained fibroblast collagen-stimulating activity.)
14. Tsai WC, Hsu CC, Chung CY, Lin MS, Li SL, Pang JH. The pentapeptide KTTKS promoting the expressions of type I collagen and transforming growth factor-beta of tendon cells. J Orthop Res. 2007;25(12):1629-1634. doi:10.1002/jor.20455. (KTTKS upregulates α1(I) procollagen, stabilizes procollagen mRNA, and increases TGF-β secretion in tendon-derived fibroblasts — mechanistic support extending beyond skin.)
15. Osborne R, Mullins L, Jarrold B, Lintner K. In vitro skin structure benefits with a new antiaging peptide, Pal-KT. J Am Acad Dermatol. 2005;52(3 Suppl):P34. (AAD-meeting abstract on Pal-KT / Pal-KTTKS cosmetic evaluation; Procter & Gamble / Sederma collaboration.)
16. Osborne R, Robinson LR, Mullins L, Raleigh P. Use of a facial moisturizer containing palmitoyl pentapeptide improves the appearance of aging skin. J Am Acad Dermatol. 2005;52(3 Suppl):P112. (AAD-meeting abstract; 60-subject 8-week split-face Pal-KTTKS + niacinamide moisturizer evaluation.)
17. Personal Care Products Council, Cosmetic Ingredient Review Expert Panel. Safety Assessment of Myristoyl Pentapeptide-4, Palmitoyl Pentapeptide-4, and Pentapeptide-4 as Used in Cosmetics. CIR Final Report. March 2024. (Consolidated safety, exposure, and efficacy data for the Pal-KTTKS ingredient family — the most comprehensive regulatory-safety review available.)
18. Schagen SK. Topical Peptide Treatments with Effective Anti-Aging Results. Cosmetics. 2017;4(2):16. doi:10.3390/cosmetics4020016. (Category review situating Pal-KTTKS, Matrixyl 3000, and Matrixyl synthe'6 in the topical anti-aging peptide landscape.)
19. Katayama K, Seyer JM, Raghow R, Kang AH. Regulation of extracellular matrix production by chemically synthesized subfragments of type I collagen carboxy propeptide. Biochemistry. 1991;30(29):7097-7104. doi:10.1021/bi00243a009. (The foundational 1991 paper that identified the procollagen I C-propeptide 197–241 region as a positive extracellular-matrix regulator, leading directly to the 1993 KTTKS-minimum-sequence paper.)
20. Castelletto V, Hamley IW, Whitehouse C, Matts PJ, Osborne R, Baker ES. Self-Assembly of Palmitoyl Lipopeptides Used in Skin Care Products. Langmuir. 2013;29(29):9149-9155. doi:10.1021/la401771j. (Supramolecular self-assembly behavior of C16-GHK, C16-KT, and C16-KTTKS palmitoyl lipopeptides used in commercial Matrixyl-class cosmetics.)